Arcadia Biosciences (RKDA) Shares Down 0%

Shares of Arcadia Biosciences (NASDAQ:RKDA) were down 0% during trading on Thursday . The stock traded as low as $9.69 and last traded at $10.00. Approximately 844,543 shares traded hands during mid-day trading, an increase of 46% from the average daily volume of 579,906 shares. The stock had previously closed at $10.00.

Several analysts have commented on RKDA shares. Piper Jaffray set a $20.00 target price on shares of Arcadia Biosciences and gave the stock a “hold” rating in a research report on Wednesday, March 14th. ValuEngine downgraded shares of Arcadia Biosciences from a “hold” rating to a “sell” rating in a report on Monday, April 2nd.

The firm has a market capitalization of $27.52 million, a PE ratio of -1.46 and a beta of -5.70.

Arcadia Biosciences (NASDAQ:RKDA) last posted its quarterly earnings data on Wednesday, May 9th. The basic materials company reported ($4.86) earnings per share (EPS) for the quarter. The firm had revenue of $0.21 million for the quarter. Arcadia Biosciences had a negative return on equity of 259.46% and a negative net margin of 686.10%.

In related news, Director Eric J. Rey sold 5,000 shares of the company’s stock in a transaction on Friday, March 23rd. The shares were sold at an average price of $33.44, for a total transaction of $167,200.00. Following the completion of the sale, the director now directly owns 12,335 shares of the company’s stock, valued at approximately $412,482.40. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Eric J. Rey sold 21,255 shares of the company’s stock in a transaction on Thursday, March 15th. The stock was sold at an average price of $45.38, for a total transaction of $964,551.90. Following the sale, the director now directly owns 28,340 shares of the company’s stock, valued at $1,286,069.20. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 28,005 shares of company stock valued at $1,189,047. 25.90% of the stock is owned by insiders.

An institutional investor recently bought a new position in Arcadia Biosciences stock. Sabby Management LLC bought a new stake in shares of Arcadia Biosciences (NASDAQ:RKDA) in the 1st quarter, according to its most recent filing with the SEC. The institutional investor bought 150,376 shares of the basic materials company’s stock, valued at approximately $3,611,000. Arcadia Biosciences comprises approximately 0.4% of Sabby Management LLC’s investment portfolio, making the stock its 10th biggest holding. Sabby Management LLC owned 6.06% of Arcadia Biosciences at the end of the most recent quarter. 31.48% of the stock is owned by institutional investors.

Arcadia Biosciences Company Profile

Arcadia Biosciences, Inc, an agricultural food ingredient company, develops and commercializes health and nutrition ingredient traits worldwide. The company offers a suite of agricultural productivity traits, including nitrogen use efficiency, water use efficiency and drought tolerance, salinity tolerance, and herbicide tolerance traits.

Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit